期刊
DRUG DEVELOPMENT AND INDUSTRIAL PHARMACY
卷 37, 期 4, 页码 475-481出版社
TAYLOR & FRANCIS LTD
DOI: 10.3109/03639045.2010.522193
关键词
Baicalin; solid lipid nanoparticles; ocular drug delivery system; pharmacokinetics; microdialysis
资金
- International Science Cooperation Project (China) [2007DFC 31670]
- National Key Technology Research and Development Program [2007BAI47B01, 2009ZX09311-002]
- Program for Changjiang Scholars and Innovative Research Team in University
Purpose: To prepare and evaluate the solid lipid nanoparticles of baicalin (BA-SLN) for ocular drug delivery system. Methods: The BA-SLN was prepared by emulsification/ultrasonication method. The appearance of BA-SLN was examined by the negative stain method. The mean diameter and zeta potential of BA-SLN were determined using a Zetasizer. The entrapment efficiency of BA-SLN was determined by Sephadex-G50 column. And the solid-state characterization of BA-SLN was analyzed by DSC and X-ray. The release of drug from BA-SLN was evaluated using dialysis bag diffusion technique. The effects of SLN on corneal permeability of baicalin were investigated in vitro, using isolated rabbit corneas. The in vivo ocular irritation of BA-SLN was tested by pathological section observation using rabbits. The pharmacokinetics was evaluated by microdialysis in the rabbit aqueous humors. Results: The results showed that the BA-SLN had an average diameter of 91.42 +/- 1.02 nm with a zeta potential of -33.5 +/- -1.28 mV and the entrapment efficiency of 62.45 +/- 1.67%. In vitro release studies indicated that the BA-SLN retained the drug entity better than the baicalin ophthalmic solutions (BA-SOL). In the pharmacokinetics studies, the AUC value of BA-SLN was 4.0-fold versus the BA-SOL (P < 0.01), and the Cmax value of BA-SLN versus the BA-SOL was 5.3-fold (P < 0.01). Conclusion: SLN can be used as a carrier to enhance ocular bioavailability of baicalin.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据